伴疼痛性与无痛性多神经病变的2型糖尿病患者皮肤神经纤维丢失与再生模式
本横断面研究对比近期起病2型糖尿病者、伴疼痛性(DSPN+p)或无痛性(DSPN-p)糖尿病感觉运动多神经病变者及糖耐量正常志愿者的皮肤活检,发现两DSPN组表皮内神经纤维密度与长度均降低且组间无差异,而真皮神经纤维再生标志物比值在DSPN+p最高,且与表皮内神经纤维丢失程度呈负相关。
要点
- DSPN+p与DSPN-p两组表皮内神经纤维密度和长度均低于对照组,但两组间无差异。
- 真皮神经纤维GAP-43/PGP9.5比值DSPN+p组高于DSPN-p组和对照组。
- 2型糖尿病者该比值与PGP9.5阳性表皮内神经纤维密度及真皮神经纤维长度呈负相关。
核心结论
- DSPN患者真皮神经纤维再生增强,尤其在DSPN+p中更明显,并随表皮内神经纤维丢失加重而增加。
- 这些数据提示尽管表皮纤维进行性丢失,真皮神经修复仍保留,尤其在DSPN+p中,但不足以充分抵消表皮神经退行性过程。
研究设计与样本
- 横断面研究,皮肤活检取自小腿远端外侧。
- 近期起病2型糖尿病者来自德国糖尿病研究(n=32),DSPN+p者(n=34)和DSPN-p者(n=32)来自PROPANE研究,糖耐量正常志愿者(n=50)。
- 采用蛋白基因产物9.5(PGP9.5)与生长相关蛋白43(GAP-43)双重免疫荧光染色评估表皮内神经纤维密度、长度及真皮神经纤维长度。
- DSPN按改良多伦多共识(2011)标准诊断,神经病理性疼痛采用11点数字评定量表评估。
主要发现
- 校正年龄、性别、BMI和HbA1c后,近期起病糖尿病组和两个DSPN组中两种标志物的表皮内神经纤维密度和长度均较对照组降低(均p<0.05),但DSPN两组间无差异。
- 真皮神经纤维GAP-43/PGP9.5比值在DSPN+p组为1.18±0.28、DSPN-p组为1.07±0.10,均高于对照组1.02±0.10(p≤0.05);DSPN+p组高于DSPN-p组(p<0.05)。
- 2型糖尿病者中,真皮神经纤维GAP-43/PGP9.5比值与PGP9.5阳性表皮内神经纤维密度(β=-0.569)及真皮神经纤维长度(β=-0.639)呈负相关(均p<0.0001),对照组无此关联。
- 真皮神经纤维GAP-43/PGP9.5比值与周围神经功能检查的相关性呈相似模式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The determinants and mechanisms of the development of diabetic sensorimotor polyneuropathy as a painful (DSPN+p) or painless (DSPN-p) entity remain unclear. We examined the degree of cutaneous nerve fibre loss and regeneration in individuals with type 2 diabetes with DSPN+p or DSPN-p compared with individuals with recent-onset type 2 diabetes and corresponding healthy volunteers. METHODS: In this cross-sectional study, skin biopsies taken from the distal lateral calf were obtained from individuals with recent-onset type 2 diabetes (n = 32) from the German Diabetes Study, with DSPN+p (n = 34) and DSPN-p (n = 32) from the PROPANE study, and volunteers with normal glucose tolerance (n = 50). Double immunofluorescence staining for protein gene product 9.5 (PGP9.5) (pan-neuronal marker) and growth-associated protein 43 (GAP-43) (nerve regeneration marker) was applied to assess intraepidermal nerve fibre density (IENFD) and length (IENFL) and dermal nerve fibre length (DNFL). DSPN was diagnosed using the modified Toronto Consensus (2011) criteria, while neuropathic pain was assessed using an 11-point Numerical Rating Scale. RESULTS: After adjustment for age, sex, BMI and HbA1c, IENFD and IENFL were reduced for both markers in individuals with recent-onset diabetes and both DSPN groups compared with control participants (all p < 0.05), but did not differ between the DSPN groups. The DNFL GAP-43/PGP9.5 ratio was higher in the DSPN+p and DSPN-p groups compared with control participants (1.18 ± 0.28 and 1.07 ± 0.10 vs 1.02 ± 0.10; p ≤ 0.05) and in the DSPN + p group compared with DSPN-p (p < 0.05). Correlation analyses showed distinct inverse associations between the DNFL GAP-43/PGP9.5 ratio and PGP9.5 positive IENFD as well as DNFL (IENFD: β = -0.569, DNFL: β = -0.639; both p < 0.0001) in individuals with type 2 diabetes, but not in the control group. A similar pattern was found for correlations between the DNFL GAP-43/PGP9.5 ratio and peripheral nerve function tests. CONCLUSIONS/INTERPRETATION: Dermal nerve fibre regeneration is enhanced in DSPN, particularly in DSPN+p, and increases with advancing intraepidermal nerve fibre loss. These data suggest that, despite progressive epidermal fibre loss, dermal nerve repair is preserved, particularly in DSPN+p, but fails to adequately counteract epidermal neurodegenerative processes.
引用
- Bönhof GJ, Strom A, Püttgen S, et al. Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. Diabetologia. 2017. PMID: 28914336. doi:10.1007/s00125-017-4438-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。